Analysts Set Amicus Therapeutics, Inc. (NASDAQ:FOLD) PT at $18.70

Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) have been given an average recommendation of “Hold” by the fourteen research firms that are covering the company, Marketbeat Ratings reports. Seven investment analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $18.70.

Several analysts have weighed in on the company. Chardan Capital reaffirmed a “neutral” rating on shares of Amicus Therapeutics in a report on Thursday, July 1st. Berenberg Bank initiated coverage on Amicus Therapeutics in a research report on Thursday, July 1st. They set a “hold” rating and a $14.00 price objective on the stock. JPMorgan Chase & Co. upgraded Amicus Therapeutics from a “neutral” rating to an “overweight” rating and reduced their price objective for the company from $17.11 to $16.00 in a research report on Thursday, September 30th. SVB Leerink reduced their price objective on Amicus Therapeutics from $13.00 to $12.00 and set a “market perform” rating on the stock in a research report on Thursday, September 30th. Finally, BTIG Research initiated coverage on Amicus Therapeutics in a research report on Monday, July 19th. They set a “buy” rating and a $15.00 price objective on the stock.

FOLD traded down $0.12 during trading on Monday, reaching $11.30. 5,508 shares of the company were exchanged, compared to its average volume of 2,992,707. The company’s 50-day moving average is $10.86 and its two-hundred day moving average is $10.05. The company has a market cap of $3.01 billion, a price-to-earnings ratio of -11.90 and a beta of 1.10. The company has a quick ratio of 4.08, a current ratio of 4.29 and a debt-to-equity ratio of 1.83. Amicus Therapeutics has a 12-month low of $8.60 and a 12-month high of $25.39.

Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings results on Wednesday, August 4th. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.03. Amicus Therapeutics had a negative return on equity of 91.47% and a negative net margin of 89.53%. The firm had revenue of $77.41 million for the quarter, compared to analysts’ expectations of $71.35 million. Equities analysts forecast that Amicus Therapeutics will post -0.79 earnings per share for the current year.

In other Amicus Therapeutics news, CEO John F. Crowley sold 37,000 shares of the stock in a transaction that occurred on Thursday, August 5th. The stock was sold at an average price of $10.03, for a total value of $371,110.00. Following the completion of the sale, the chief executive officer now owns 884,345 shares in the company, valued at approximately $8,869,980.35. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO John F. Crowley sold 22,000 shares of the firm’s stock in a transaction that occurred on Monday, August 16th. The shares were sold at an average price of $10.27, for a total value of $225,940.00. Following the completion of the transaction, the chief executive officer now owns 869,345 shares of the company’s stock, valued at approximately $8,928,173.15. The disclosure for this sale can be found here. In the last quarter, insiders acquired 4,500 shares of company stock valued at $45,375 and sold 153,266 shares valued at $1,616,438. Company insiders own 2.10% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in FOLD. Royal Bank of Canada raised its stake in Amicus Therapeutics by 400.0% during the first quarter. Royal Bank of Canada now owns 138,772 shares of the biopharmaceutical company’s stock valued at $1,370,000 after buying an additional 111,017 shares during the last quarter. Brookfield Asset Management Inc. bought a new stake in shares of Amicus Therapeutics in the 1st quarter worth $4,739,000. Trexquant Investment LP increased its holdings in shares of Amicus Therapeutics by 46.2% in the 1st quarter. Trexquant Investment LP now owns 79,793 shares of the biopharmaceutical company’s stock worth $788,000 after purchasing an additional 25,201 shares in the last quarter. Deutsche Bank AG increased its holdings in shares of Amicus Therapeutics by 14.1% in the 2nd quarter. Deutsche Bank AG now owns 8,344,730 shares of the biopharmaceutical company’s stock worth $80,443,000 after purchasing an additional 1,030,803 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd increased its holdings in shares of Amicus Therapeutics by 325.2% in the 1st quarter. Y Intercept Hong Kong Ltd now owns 62,072 shares of the biopharmaceutical company’s stock worth $583,000 after purchasing an additional 47,475 shares in the last quarter.

About Amicus Therapeutics

Amicus Therapeutics, Inc operates as a biotechnology company. The firm focuses on discovering, developing and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio.

Featured Article: Channel Trading

Analyst Recommendations for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.